Sangamo BioSciences Stock News

Pfizer Inc. (NYSE: PFE) andSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvov

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. The Alta study data, in patients with severe hemophilia A, are being presented today at the 63rd American Society for Hematology Annual Meeting and Exposition t

No adverse events related to investigational SAR445136 were reported - All four treated patients experienced increases in total hemoglobin, fetal hemoglobin and percent F cells; none required bloo

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease (SCD). These data are being presented today at the 63rd American Society for Hematology Annual Meeting and Exposition taking place from December 11-14

Shares of Sangamo Therapeutics, Inc. reached a new 52-week low during mid-day trading on Friday following insider selling activity. The stock traded as low as $7.75 and last

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) reached a new 52-week low during mid-day trading on Friday following insider selling activity. The stock traded as low as $7.75 and last traded at $7.76, with a volume of 66523 shares. The stock had previously closed at $8.14. Specifically, major shareholder Biogen Inc. sold 52,178 shares of the [] The post Sangamo Therapeutics (NASDAQ:SGMO) Sets New 12-Month Low Following Insider Selling appeared first on ETF Daily News .

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) major shareholder Biogen Inc. sold 52,178 shares of Sangamo Therapeutics stock in a transaction that occurred on Tuesday, December 7th. The shares were sold at an average price of $8.52, for a total transaction of $444,556.56. The transaction was disclosed in a filing with the SEC, which is available at this []

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) major shareholder Biogen Inc. sold 28,884 shares of the companys stock in a transaction dated Friday, November 26th. The stock was sold at an average price of $8.60, for a total transaction of $248,402.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through []

Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December

Morgan Stanley increased its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 24.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 891,147 shares of the biopharmaceutical companys stock after purchasing an additional 176,775 shares during the quarter. Morgan Stanleys holdings in Sangamo []

Metropolitan Life Insurance Co NY increased its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 108,530.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,848 shares of the biopharmaceutical companys stock after purchasing an additional 35,815 shares during the quarter. Metropolitan Life []

Wall Street analysts forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will announce sales of $29.15 million for the current quarter, Zacks reports. Four analysts have provided estimates for Sangamo Therapeutics earnings. The highest sales estimate is $32.00 million and the lowest is $28.00 million. Sangamo Therapeutics posted sales of $25.80 million during the same quarter last []

Amalgamated Bank boosted its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 32.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,611 shares of the biopharmaceutical companys stock after acquiring an additional 5,247 shares during the quarter. Amalgamated Banks holdings in Sangamo Therapeutics []

Sangamo Therapeutics Inc. (NASDAQ:SGMO) price on Thursday, November 18, fall -2.10% below its previous days close as a downside momentum from buyers pushed the stocks value to $9.32. A look at the stocks price movement, the close in the last trading session was $9.52, moving within a range at $9.265 and $9.67. The beta value Honey At Sangamo Therapeutics Inc. (SGMO) Is Worth Your Money Read More »